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Summary A cell line (SMKT-R3) established from human renal cell carcinoma was characterised for the
presence of sulfolipids and glycolipid sulfotransferases. Sulfolipids were found to constitute a large part of the
acidic glycolipid fraction in SMKT-R3 cells. These findings were confirmed by metabolic labelling with
IIS-sulfate. These sulfolipids were expressed at the surface of SMKT-R3 cells as ascertained by cyto-
fluorometry using a monoclonal antibody directed to sulfolipids. Furthermore, markedly high activity levels of
glycolipid sulfotransferases were observed in SMKT-R3 cells compared with other cell lines. These results
suggest that the increased synthesis of sulfolipids in renal cell carcinoma tissue (Sakakibara et al., 1989. Cancer
Res., 49, 335-339) is due to the elevation of the sulfotransferase activities of renal carcinoma cells themselves.
Glycolipids have been known to undergo marked cancer-
associated changes (Hakomori, 1985). In particular, acidic
glycolipids with sialic acid residues, called gangliosides, have
been well studied. On the other hand, reports on cancer-
associated changes of the other acidic glycolipids, sulfolipids,
which contain sulfate residues, are relatively rare (Siddiqui et
al., 1978; Gasa et al., 1979; Yoda et al., 1979; Hattori et al.,
1981; Mitsuyama et al., 1983; Hiraiwa et al., 1988; Hiraiwa et
al., 1990). The synthesis of sulfolipids is catalysed by
PAPS:GalCer sulfotransferase (EC 2.8.2.11) (Balasu-
bramanian & Bachhawat, 1965). Although the sulfotrans-
ferase from rat kidney (Tennekoon et al., 1985) and testis
(Sakac et al., 1992) has been recently purified, the human
enzyme has not.
In our previous studies, sulfolipids were found to increase
markedly in human renal cell carcinoma (Sakakibara et al.,
1989), but not in Wilms' tumour (Sakakibara et al., 1991).
The increment of the sulfolipid contents in renal cell car-
cinoma was associated with enhanced activity of glycolipid
sulfotransferase in the cancer tissues (Sakakibara et al.,
1989). Furthermore, the level of the sulfotransferase appeared
to be elevated in sera from patients with renal cell carcimona
(Gasa et al., 1990), and hepatocellular carcinoma (Gasa et
al., 1991).
Several cell lines established from mammalian kidney were
characterised for sulfotransferase activity (Tadano &
Ishizuka, 1979), but there has been no report on the enzyme
activity and sulfolipids of renal cell carcinoma cells. This
paper describes some properties of sulfolipids and glycolipid
sulfotransferase activities in renal cell carcinoma cells.
Materials and methods
Materials
5S-PAPS (L.5 Cimmol-') and 35S-sodium sulfate (250-1000
mCi mmol-') were purchased from New England Nuclear;
unlabeled PAPS and p-nitrocatechol sulfate from Sigma.
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DEAE-Sephadex A-25 and Sephadex G-25 were obtained
from Pharmacia-LKB. GalCer and LacCer were purified in
this laboratory from bovine brain and horse red cell mem-
branes, respectively. Other reagents were of analytical grade.
Several human cell lines, A-431 (epidermoid carcinoma),
PC-3 (lung adenocarcinoma), HL-60 (acute promyelocyte
leukaemia), K-562 (chronic myelogenous leukaemia), were a
gift from the Japanese Cancer Research Resources Bank.
Cell culture
SMKT-R3 cells were established from human renal cell car-
cinoma as described previously (Miyao et al., 1989), and
cultured in Dulbecco's modified minimal essential medium
supplemented with 10% foetal bovine serum.
Preparation ofglycolipids
Cell monolayers were washed with Tris-buffered saline and
harvested by scraping with a rubber policeman. Then the cell
suspensions were centrifuged and washed three times with
Tris-buffered saline. The cell pellets (approximately 10 mg
protein) were extracted with 50 ml of a mixture of
chloroform/methanol/water (60:35:8, the ratio of the solvent
mixture is expressed by volume), and then re-extracted with
50 ml of a mixture of chloroform/methanol/water (30:60:8).
The two extracts were combined and subjected to mild
alkaline hydrolysis to destroy ester lipids, followed by neutra-
lisation with acetic acid. After evaporation of the solvent, the
total lipid extract was desalted with a Sephadex G-25 col-
umn. The eluate was concentrated and applied to a DEAE-
Sephadex A-25 (acetate form) column. After washing with
chlorofom/methanol/water (30:60:8), the acidic glycolipid
fraction was eluated with chloroform/methanol/I M
CH3COONH4 (30:60:8), evaporated, and desalted as above.
Analysis ofglycolipids
Glycolipids were chromatographed on precoated Silica Gel
60 HPTLC plates (Merck) using the solvent system:
chloroform/methanol/0.2% CaCl2 (60:35:7). Orcinol, resor-
cinol, and Azure A reagents were used for detection of
hexose-containing glycolipids (Svennerholm, 1956), gang-
liosides (Svennerholm, 1957), and sulfolipids (Iida et al.,
1989), respectively. TLC-immunostaining was performed
using an anti-sulfolipid monoclonal antibody, Sulph I (Fred-
man et al., 1988), and peroxidase-conjugated sheep anti-
mouse immunoglobulins as described previously (Magnani et
al., 1982).
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Metabolic labelling ofSMKT-R3 cells
Monolayer cultures of SMKT-R3 cells (3 x 106 cells) were
labelled with 5tLCi ml1 35S-sodium sulfate for 24 h. Labelled
acidic glycolipids were prepared, chromatographed as des-
cribed above, and detected by autoradiography.
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Assay ofglycolipid sulfotransferase activities andidentification
ofthe reaction products
The cell pellets, which were prepared as above, were
resuspended in 10mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1%
Lubrol PX and sonicated on ice. Glycolipid sulfotransferase
activities of the cell homogenate, the protein concentration of
which was adjusted to approximately 1 mg ml 1, were
assayed using GalCer and LacCer separately as substrates by
a previously described method (Kawano et al., 1989). The
minimal detectable level of the assay was 30-50pmolh-'
mg-' protein. The synthesised products were isolated,
desalted, chromatographed on a TLC plate, and scanned for
radioactivity, according to a previous procedure (Kawano et
al., 1989).
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0 Assay ofarylsulfatase A activity
Arylsulfatase A activity of the cell homogenate was assayed
by the method of Baum et al. (1965).
Cytofluorometric analysis
SMKT-R3 cells were incubated for 24 h in the culture
medium with or without 0.5 mM sodium selenate. The cells
were harvested, washed, and stained by the indirect immuno-
fluorescence method; the cells were reacted with Sulph I as
the first antibody and subsequently with fluorescein
isothiocyanate-conjugated F(ab')2 fragment of rabbit anti-
mouse immunoglobulins (DAKO) as the second antibody.
Fluorescence profiles were determined with a FACScan (Bec-
ton Dickinson).
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Figure 2 Detection of cell surface expression of sulfolipids by
flow cytometry. SMKT-R3 cells were cultured in the presence
(lower) or absence (upper) of sodium selenate. The cells were
reacted with the monoclonal antibody Sulph I, and fluorescein-
conjugated F(ab')2 to mouse IgG, followed by flow cytometry.
The solid line indicates reactivity with Sulph I; the dotted line,
reactivity with nonspecific isotype mouse IgG.
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Figure 1 Thin-layer chromatogram of acidic glycolipids from SMKT-R3 cells. 0, origin. a, Lanes 1,3 and 5, sulfolipid standards:
SM4, SM3, SM2 and SB2 from the top to the bottom; lanes 2, 4 and 5, acidic glycolipids from SMKT-R3 cells, each
corresponding to I mg of cell protein. Glycolipids were chromatographed and visualised with an orcinol reagant (lanes 1 and 2), or
with an azure A reagent (lanes 3 and 4) or by immunostaining (lanes 5 and 6) as described under 'Materials and methods'. b, Lane
1, sulfolipid standards stained with an orcinol reagent as shown in a. Lane 2, autoradiogram of a TLC plate of labelled SMKT-R3
cell lipids. The cells were metabolically labelled with "S-sulfate. Acidic glycolipids extracted from the cells, corresponding to 300fig
of cell protein were chromatographed and detected by autoradiography. Minor sulfolipids are marked with asterisks.
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Results
Acidic glycolipidsfrom human renal cell carcinoma cells
When acidic glycolipid fractions extracted from SMKT-R3
cells were analysed by TLC, a number of glycolipids were
detected as shown in Figure la. Three of them, co-migrating
with authentic SM4, SM3, and SM2, were found to be
negative with resorcinol reagent (data not shown) but
positive with Azure A reagent as well as with orcinol reagent.
The monoclonal antibody Sulph I, which recognises non-
reducing terminal galactose-3-O-sulfate (Fredman et al.,
1988), reacted specifically with the cell glycolipids consistent
with standard SM4 and SM3. Taken together, the three
glycolipids were identified as sulfolipids. These sulfolipids
appeared as doublets, probably due to heterogeneity of the
lipic moiety. Thus sulfolipids constituted a large part of the
acidi glycolipid fraction in SMKT-R3 cells. These observa-
tions were confirmed by metabolic labelling with 35S-sulfate
as shown in Figure lb. Five sulfolipids were detected by
autoradiography of the thin-layer chromatogram of the
acidic glycolipid extract from the cells. In addition to the
sulfolipids corresponding to reference SM4, SM3 and SM2,
two minor, more slowing migrating sulfolipids (asterisks)
were also detected, but they remain to be characterised.
Cytofluorometric analysis ofSMKT-R3 cells
In order to ascertain sulfolipid expression on the cell surface,
SMKT-R3 cells were analysed with a fluorescence-activated
cell sorter using the monoclonal antibody Sulph I. As shown
in Figure 2 (upper), Sulph I gave good cell surface reactivity
with SMKT-R3 cells. Incubation of the cells with sodium
selenate, which inhibits the synthesis of sulfolipids (Aruffo et
al., 1991), resulted in a reduction of expression of these
sulfolipids (Figure 2 lower).
Characterisation ofglycolipid sulfotransferase ofSMKT-R3
cells
We previously established a rapid procedure for the deter-
mination of glycolipid sulfotransferase activity using rat
kidney tissue as an enzyme source (Kawano et al., 1989).
SMKT-R3 cell homogenates were examined to detect the
sulfotransferase activity through this assay procedure. When
GalCer and LacCer were separately used as substrates, the
products co-migrated with authentic SM4 and SM3, respec-
tively, confirming the presence of glycolipid sulfotransferase
activities and the validity of utilising this assay method
(Figure 3). The effect of substrate concentration on the sulfo-
transferase activities of SMKT-R3 cells is shown in Figure 4.
The Km values of the enzyme for GalCer and LacCer cal-
culated from a Lineweaver-Burk plot were 43.2tiM and
358JiM, respectively.
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Figure 3 Characterisation of radiolabelled products of the
glycolipid sulfotransferase reactions. Labelled sulfolipids syn-
thesised by the sulfotransferases of SMKT-R3 cell homogenates
were extracted, chromatographed on a thin-layer plate, and scan-
ned for radioactivity. a, Sulfolipid standards stained with an
orcinol reagent. b, Labelled product from GalCer substrate. c,
Labelled product from LacCer substrate. 0, origin.
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Figure 4 Effect of substrate concentrations on glycolipid sulfo-
transferase activities of SMKT-R3 cells. GalCer (0) and LacCer
(0) were separately used as substrates. The obtained Lineweaver-
Burk plots are shown.
Glycolipid sulfotransferase andarylsulfatase A activities in
various human cell lines
Various human cell lines were evaluated to determine wheth-
er the sulfotransferase activities were characteristic of renal
cell carcinoma cells or not. Interestingly, the sulfotransferase
activities could not be detected in the cell lines other than
SMKT-R3 under our assay conditions (Table I). The specific
activities of glycolipid sulfotransferase toward GalCer and
LacCer were 8690 pmol h-' mg-' protein and 3015 pmol
h-' mg-' protein, respectively. On the other hand, the
activities of arylsulfatase A, which catalyses hydrolysis of
sulfolipids, were not significantly different in these cell lines
(Table I). Therefore, it was suggested that the accumulation
of sulfolipids in SMKT-R3 cells was due to their increased
synthesis, and that the elevated sulfotransferase activities
were unique to renal cell carcinoma cells.
Discussion
In our previous study, a significantly elevated level of
glycolipid sulfotransferases associated with accumulation of
sulfolipids was demonstrated in human renal cell carcinoma
tissues (Sakakibara et al., 1089). These findings were
confirmed and carried forward by the present study, where
sulfolipids and glycolipid sulfotransferases were found to be
expressed in renal cell carcinoma cells themselves.
The glycolipid patterns and the sulfotransferase activities
of other human renal cell carcinoma cell lines, SMKT-RI
and SMKT-R2, (Miyao et al., 1989) were similar to those of
SMKT-R3 (data not shown). Glycolipid sulfotransferase
activities could be detected only in renal cell carcinoma cell
lines as far as we could examine, although there are reports
documenting the expression of sulfolipids in other tumour
cell lines including HL-60 cells (Hiraiwa et al., 1988; Krivan
et al., 1989; Hiraiwa et al., 1990; Aruffo et al., 1991). When
acidic glycolipid fractions from the other cell lines than the
renal cell carcinoma cells were examined on TLC, sulfolipids
could not be detected (data not shown). Our observations are
consistent with the fact that the preferential expression of
sulfated glycolipids is tissue-specific and relatively restricted
to brain, kidney and small intestine (Makita & Taniguchi,
1985).
The specific activity of sulfotransferase towards GalCer in
SMKT-R3 cells was 50-fold greater than that in normal
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Table 1 Activity levels of glycolipid sulfotransferases and arylsulfatase A in various human cell lines
Galactosyceramide Lactosylceramide
sulfotransferase sulfotransferase Arylsulfatase A
Cell Origin (pmolh' -mg-') (pmolh--mg-') (nmolh-' mg-')
SMKT-R3 Renal cell carcinoma 8690 3015 207
PC-3 Lung adenocarcinoma N.D.a N.D. 128
A-431 Epidermoid carcinoma N.D. N.D. 148
HL-60 Acute promyelocyte leukaemia N.D. N.D. 110
K-562 Chronic myelogenous leukaemia N.D. N.D. 224
Fibroblast Normal skin N.D. N.D. 213
aN.D., Not detected.
human kidney tissue, and 8-fold greater than that in renal
cell carcinoma tissue as shown in our previous report
(Sakakibara et al., 1989). Similar results were obtained as to
LacCer sulfotransferase activity (Sakakibara et al., 1989).
Since human renal cell carcinoma is thought to originate
from proximal tubular cells (Tannenbaum et al., 1971), one
of the reasons for the difference of the specific activities
between renal cell carcinoma tissues and cells may be that the
tissues contain other histological cells such as stromal cells
that do not express the sulfotransferase activities. Further-
more, the specific activities for the sulfotransferase in SMKT-
R3 cells were much greater than those in MDCK cells and
JTC-12 cells, which were isolated from dog and monkey
kidney, respectively (Tadano & Ishizuka, 1979), although the
assay conditions were slightly different. Taken together, it is
suggested that the sulfotransferase activities are characteristic
of renal cells, and that the elevation of the enzymes is caused
by the malignant changes of renal cells.
The sulfotransferase preparation from SMKT-R3 cells
could sulfate GalCer and LacCer. Competition studies have
suggested that GalCer and LacCer are sulfated by a single
enzyme in MDCK cells and JTC-12 cells (Tadano &
Ishizuka, 1979). Similar results were obtained from rat
and boar testis sulfotransferases (Handa et al., 1974; Ling-
wood, 1985). The Km value for GalCer of the sulfotrans-
ferase from SMKT-R3 cells was smaller than that for LacCer
(Figure 4), in good concordance with those from MDCK
cells and JTC-12 cells (Tadano & Ishizuka, 1979). Therefore,
the sulfotransferase appears to prefer GalCer to LacCer as a
substrate. In fact, the specific activity for GalCer was higher
than that for LacCer in SMKT-R3 cells within a limited
amount of substrate.
The SM3 content was much greater than that of SM4
(Figure 1), although more monohexosylceramides than di-
hexoslyceramides were contained in the neutral fraction of
SMKT-R3 cells (data not shown). Human kidney contains
GalCer and GlcCer as monohexosylceramide with a higher
content of GlcCer, and the ratio of GlcCer in renal cell
carcinoma tissues increases compared with that in uninvolved
tissues (Saga et al., 1990). Therefore, the amount of precur-
sor glycolipids may regulate the synthesis of sulfolipids. One
other explanation for the discrepancy may be that SM4 is
more easily degraded by hydrolases, including arylsulfatase
A, than SM3 in renal carcinoma cells.
Sulfolipids have been demonstrated to have a variety of
biological interactions with extracellular matrix and blood
coagulation modulators, etc. (Roberts, 1987). SMKT-R3 cells
provide a useful model system for studying such sulfolipid
functions as well as various aspects of glycolipid sulfotrans-
ferases and the sulfolipid metabolism in renal cancer cells.
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